Dr. Matthias Schnell, Director of the Jefferson Vaccine Center at Thomas Jefferson University is co-developing a broad-acting Ebola vaccine together with the National Institutes of Health (NIH). The team has already created the vaccine construct, and are in the process of manufacturing it for human administration. Dr. Schnell has also applied for grants to develop large quantities of serum for the treatment of already infected Ebola patients. Dr. Schnell is currently abroad, but available for comment.